We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+20.93%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$952M
AUM Growth
+$119M
Cap. Flow
-$4.06M
Cap. Flow %
-0.43%
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$23.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$16.8M
4
TVTX icon
Travere Therapeutics
TVTX
+$16.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$15.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$48M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.8M
3
MNKD icon
MannKind Corp
MNKD
+$19.8M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.36%
2 Miscellaneous 16.85%
3 Consumer Staples 1.74%
4 Technology 0.04%
5 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
101
Rigel Pharmaceuticals
RIGL
$829M
$194K 0.02%
+5,000
New +$178K
FLNA
102
Filana Therapeutics
FLNA
$33.6M
$194K 0.02%
5,072
– –
CSLT
103
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$180K 0.02%
+8,500
New +$246K
HNT
104
DELISTED
HEALTH NET INC
HNT
$179K 0.02%
5,275
-267,500
-98% -$8.78M
DVA icon
105
DaVita
DVA
$12.2B
$164K 0.02%
2,382
– –
VCRA
106
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$163K 0.02%
+10,000
New +$169K
CNC icon
107
Centene
CNC
$33.4B
$162K 0.02%
10,440
– –
IPXL
108
DELISTED
Impax Laboratories, Inc.
IPXL
$158K 0.02%
5,962
– –
MDSO
109
DELISTED
Medidata Solutions, Inc.
MDSO
$152K 0.02%
2,802
-840
-23% -$51.2K
HUM icon
110
Humana
HUM
$47.6B
$141K 0.01%
+1,250
New +$130K
PCRX icon
111
Pacira BioSciences
PCRX
$960M
$139K 0.01%
+2,000
New +$136K
HZNP
112
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$138K 0.01%
+9,120
New +$103K
LAB icon
113
Standard BioTools
LAB
$271M
$135K 0.01%
3,070
+1,040
+51% +$45.8K
ABMD
114
DELISTED
Abiomed Inc
ABMD
$130K 0.01%
+5,000
New +$138K
ALR
115
DELISTED
Alere Inc
ALR
$127K 0.01%
3,700
-427
-10% -$15.6K
CI icon
116
Cigna
CI
$76.3B
$106K 0.01%
1,269
-123,731
-99% -$10.2M
OCR
117
DELISTED
OMNICARE INC
OCR
$103K 0.01%
1,732
-760
-30% -$46.1K
RAD
118
DELISTED
Rite Aid Corporation
RAD
$94K 0.01%
746
– –
ENDP
119
DELISTED
Endo International plc
ENDP
$78K 0.01%
1,138
– –
PBYI icon
120
Puma Biotechnology
PBYI
$477M
$76K 0.01%
735
– –
TXMD icon
121
TherapeuticsMD
TXMD
$25M
$44K ﹤0.01%
+140
New +$44.6K
STML
122
DELISTED
Stemline Therapeutics, Inc.
STML
$1K ﹤0.01%
38
– –
AXGN icon
123
Axogen
AXGN
$2.42B
– –
-4,500
Closed -$20K
AZN icon
124
AstraZeneca
AZN
$251B
– –
-2,558
Closed -$152K
BCRX icon
125
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-197,500
Closed -$1.5M
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors's Q1 2014 filing shows 60 new, 16 increased, 31 reduced and 41 closed positions. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M. The largest sale was Celgene Corp, an estimated $48M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
  • Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
  • Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
  • Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
  • Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.

Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.